Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NRP1 | O14786 | 2/20 | 0.42 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.38 |
| ▸ | RAMP3 | O60896 | 6/20 | 0.37 |
| ▸ | CALCR | P30988 | 6/20 | 0.37 |
| ▸ | GRB2 | P62993 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26419823 | 1.00 | NRP1 (0.42) | NRP1EPHA2OPRM1OPRK1RAMP3 | |
| SCHEMBL22861995 | 0.87 | NRP1 (0.44) | NRP1EPHA2OPRM1OPRK1GRB2 | |
| SCHEMBL22803169 | 0.87 | NRP1 (0.45) | NRP1EPHA2OPRM1OPRK1RAMP3 | |
| SCHEMBL20694547 | 0.85 | NRP1 (0.46) | NRP1EPHA2OPRM1OPRK1RAMP3 | |
| SCHEMBL24918881 | 0.85 | MMP1 (0.34) | EPHA2RAMP3CALCRGRB2 | |
| SCHEMBL30416793 | 0.85 | NRP1 (0.46) | NRP1EPHA2OPRM1OPRK1RAMP3 | |
| SCHEMBL30452201 | 0.84 | NRP1 (0.43) | NRP1EPHA2OPRM1OPRK1GRB2 | |
| SCHEMBL24716410 | 0.84 | NRP1 (0.45) | NRP1EPHA2OPRM1OPRK1RAMP3 | |
| SCHEMBL22872708 | 0.82 | NRP1 (0.54) | NRP1EPHA2OPRM1OPRK1GRB2 | |
| SCHEMBL29571627 | 0.80 | NRP1 (0.54) | NRP1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238436-A1 | COMPOSITIONS INCLUDING CONJUGATED THERAPY ENHANCERS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-07-18 | — | — | US | disclosed |
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230028880-A1 | CD38-BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20200390895-A1 | UNIVERSAL ABT COMPOUNDS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | CD2BP2, CD2, CD47 | NRP1 2457/4885EPHA2 5/4885OPRM1 3333/4885 |
| US-20240238436-A1 | COMPOSITIONS INCLUDING CONJUGATED THERAPY ENHANCERS | LGMN, LPXN, LY96 | NRP1 2778/4885EPHA2 119/4885OPRM1 1385/4885 |
| US-20200390895-A1 | UNIVERSAL ABT COMPOUNDS AND USES THEREOF | CD47, MCL1, BCL9 | NRP1 3843/4885EPHA2 1292/4885OPRM1 4149/4885 |
| US-20230028880-A1 | CD38-BINDING AGENTS AND USES THEREOF | CD38, CD47, CD2 | NRP1 2712/4885EPHA2 1057/4885OPRM1 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.